Analysts Set Expectations for BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Bicycle Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($4.24) per share for the year. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s revenue was down 50.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.26) EPS.

Other analysts also recently issued research reports about the company. Stephens reissued an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday. B. Riley cut their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Bicycle Therapeutics in a research note on Monday, January 13th. Finally, JMP Securities decreased their price target on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $33.25.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $13.23 on Thursday. The stock’s 50 day moving average price is $16.92 and its 200 day moving average price is $21.34. The stock has a market cap of $913.53 million, a price-to-earnings ratio of -4.02 and a beta of 0.92. Bicycle Therapeutics has a 12 month low of $12.17 and a 12 month high of $28.67.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Renaissance Technologies LLC increased its stake in shares of Bicycle Therapeutics by 97.2% in the second quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares during the last quarter. XTX Topco Ltd acquired a new position in Bicycle Therapeutics in the 2nd quarter worth about $206,000. Marshall Wace LLP acquired a new position in Bicycle Therapeutics in the 2nd quarter worth about $1,801,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Bicycle Therapeutics by 923.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 96,409 shares of the company’s stock valued at $1,951,000 after buying an additional 86,989 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of Bicycle Therapeutics by 17.9% in the 2nd quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock valued at $39,913,000 after buying an additional 300,000 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Insider Buying and Selling

In other news, CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This represents a 24.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Santiago Arroyo sold 4,943 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $69,646.87. Following the sale, the insider now owns 69,057 shares of the company’s stock, valued at approximately $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,933 shares of company stock valued at $549,501. Company insiders own 8.50% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.